





Classify the main <u>antimalarial drugs</u> depending on their goal of therapy

Optimize the pharmacokinetics & dynamics of main drugs used to treat attack or prevent relapses

State the WHO therapeutic strategy for treatment

White the CDC recommendations for prophylaxis in travelers to endemic areas.



According to WHO:

212 million cases of malaria worldwide in 2015 & 429,000 deaths. 90% of malaria cases & deaths occur in Africa. Children under 5 are most at risk.

Four species of plasmodium typically cause human malaria:

- Plasmodium falciparum,
- P vivax,
- P malariae, and
- P ovale.





THERAPEUTIC CLASSIFICATION:

Causal prophylaxis

Destroys parasite in **liver** cells & prevent invasion of erythrocytes





Suppresses the **erythrocytic** phase & thus attack of malaria fever Chloroquine, mefloquine, doxycycline

ANTIMALARIAL DRUGS

THERAPEUTIC CLASSIFICATION:

Clinical cure (**Erythrocytic** schizonticide)

Fast acting high efficacy Used to terminate an episode of malarial fever

Chloroquine, quinine, mefloquine, artemisinin

Pyrimethamine, proguanil, sulfonamides⁶



ANTIMALARIAL DRUGS

THERAPEUTIC CLASSIFICATION:

Radical cure

Gametocidal

Sporozoitocides

Eradicate all forms of vivax from the body

Destroys gametocytes & prevent transmission

Destroys

sporozoites

Suppressive drug + hypnozoitocidal

Chloroquine, quinine against vivax

Primaquine, all species

Proguanil, ' pyrimethamine



@ Artemisinin is the active principle of the plant Artemisia annua (qinghaosu)

Fast acting blood Schizontocide

Affect all forms including multidrug resistant P. falciparum

Short duration of action

@ High recrudescence rate after short-course therapy



NOBEL PRIZE IN MEDICINE 2015

The Nobel Prize in Physiology or Medicine 2015 was awarded with one half jointly to William C. Campbell & Satoshi Omura & the other half to Youyou Tu.



8

Poorly soluble in water & oil, can only be used orally.

PHARMAKOKINETICS

Rapidly biotransformed in liver into di-hydroartesiminin + active metabolite

@Artemisinin, artesunate, artemether are prodrugs

e Derivatives are rapidly absorbed orally & Widely distributed

Artemisinin $t^{1/2} \rightarrow 4$ hrs

@Artesunate t½ 45 min (water-soluble; oral, IV, IM, rectal administration) **@**Artemether t½ 4-11 hrs, (lipid-soluble; oral, IM, & rectal administration). Induce its own CYP-mediated metabolism→ \uparrow , clearance 5 fold.

ARTEMESININ & ITS DERIVATIVES

MECHANISM

Artemisinin & its analogs are very rapidly acting blood schizonticides against all human malaria parasites. No effect on hepatic stages.



ARTEMESININ & ITS DERIVATIVES

MECHANISM

They have endoperoxide bridges Haem iron cleaves this bridge to yield carboncentered free radicals in parasite, that will

Alkylate membranes of parasite's food vacuole
& mitochondria > no energy

Irreversibly bind & inhibit sarco-endoplasmic reticulum Ca²⁺-ATPase of the parasite, thereby inhibiting its growth

Inhibiting formation of transport vesicles + no food vacuoles.





CLINICAL USES

Because artemisinin derivatives have short t1/2,

- (1) Monotherapy should be extended beyond disappearance of parasite to prevent recrudescence or
- (2) by combining the drug with long- acting antimalarial drugs (Ex. mefloquine)

PREPARATIONS

Artesunate IV or IM preparations for severe complicated cases as cerebral malaria (24 h) followed by complete course of ACT.



PREPARATIONS

@Artemisinin-based combination therapies (ACTs):

Artemether + lumefantrine

Artemether + amodiaquine

Artemether + mefloquine

>Artemether + sulfadoxine- pyrimethamine.









Potent **blood** Schizontocide

Active against all forms of the schizonts (exception is chloroquine-resistant P.f. & P.v.)

Not active against tissue shizonts

Gametocide:-Against all species except P. falciparum.



Chloroquit Phosphate Tablets, USP

(from Iowa State Univ. Entomology Image Gallery)



PHARMACOKINETICS

Rapidly & completely absorbed from the GIT, given po
 Has high volume of distribution (100-1000 L/kg);
 Released slowly from tissues & metabolized in liver

Concentrated into parasitized RBCs

@ Excreted in the urine 70% unchanged @ Initial $t\frac{1}{2}$ = 2-3 days & terminal elimination $t\frac{1}{2}$ =1-2 months.



CHLOROQUINE

MECHANISM OF ACTION

<u>Malaria Parasite</u> digest host cell's Hb to utilize globin & obtain amino acids

Heme is released → Toxic
So parasite detoxifies it by
heme polymerase →
Hemozoin (NonToxic) & traps
it in food vacuoles.





RESISTANCE

Resistance against the drug develops as a result of <u>mutation</u> of the chloroquine resistance transporter (PfCRT)

PfCRT enhances the efflux of chloroquine from the food vacuole.





THERAPEUTIC USES

Used to eradicate **blood** schizonts of *Plasmodium*. It is given in loading dose to rapidly achieve effective plasma conc.



Rheumatoid arthritis.



(original image provided by Steve Aley)

CHLOROQUINE



- 1. Mild headache & visual disturbances
- 2. GIT upsets; Nausea, vomiting
- 3. Pruritus, urticaria.

Prolonged therapy & high doses:

 Ocular toxicity: Loss of accommodation, lenticular opacity, retinopathy

 Ototoxicity

 Weight loss

 Bolus injection → hypotension & dysrrhythmias



The main alkaloid in cinchona bark

Potent blood Schizontocide of ALL malarial parasites & gametoside for P vivax & ovale but not falciparum. It is Not active against liver stage parasites.

@ Depresses the myocardium, reduce excitability & conductivity

Mild analgesic, antipyretic, stimulation of uterine smooth muscle, curare mimetic effect.





PHARMACOKINETICS

Rapidly & completely absorbed from the GIT

Peaks after 1-3 hours

@ Metabolized in the liver & excreted in urine

@ 5-20% excreted in the urine unchanged

 $@ t\frac{1}{2} = 10 hrs but longer in sever falciparum infection (18 hrs)$

Administered: orally in a 7 day course or by slow IV for severe P. falciparum infection.



MECHANISM Same as chloroquine

MECHANISM OF RESISTANCE Like chloroquine, by mutation of chloroquine resistance transporter, also increased expression of **P-glycoprotein transporter**.





CLINICAL USES:

Parenteral treatment of severe falciparum malaria Oral treatment of falciparum malaria Nocturnal leg cramps.





respiration & coma.





CONTRAINDICATIONS

Prolonged QT Interval

Glucose-6-Phosphate Dehydrogenase deficiency & pregnancy

Myasthenia Gravis

Optic Neuritis, auditory problems

Ose should be reduced in renal insufficiency.

Glucose-6-phosphate G-6-P-D enzyme 6- Phosphoguconate + NADPH+ H^+ In case of G-6-P-D Leads to Inadequate supply of NADPH Leads to Reduced level of Glutathione Glutathione protects Hb oxidation



DRUG INTERACTIONS

 Antacids: Antacids containing aluminum &/or magnesium may delay or decrease absorption of quinine

27

Mefloquine

• Quinine can raise plasma levels of warfarin & digoxin.

PRIMAQUINE

Pypnozoitocides against liver hypnozoites
gametocytocides against the 4 human malaria species
Radical cure of *P. ovale & P. vivax*Prevent spread of ALL forms (chemoprophylaxis)

PHARMACOKINETICS

Well absorbed orally

- Rapidly metabolized to etaquine & tafenoquine
- more active forms
- @ t½ → 3-6 h.







Not well understood, It may be acting by:-

Generating ROS + can damage lipids, proteins & nucleic acids in the parasite
 Interfering with the electron transport + no energy
 Inhibiting formation of transport vasicles + r

Inhibiting formation of transport vesicles + no food vacuoles

Resistance;

Resistance;

Rare when primaquine & chloroquine are combined.

Primaquine

Converted to electrophiles

Generates reactive oxygen species

- Interferes with oxygen transport system

8		8
		1
L	DDIMAOIIINE	
L		
Ļ		

ANTIMALARIAL DRUGS

CLINICAL USES

Radical cure of relapsing malaria, 15 mg/day for 14 days

In falciparum malaria: a single dose (45 mg) to kill gametes & cut down transmission

G-6-PD NORMAL	15mg per day x 14
G-6-PD deficiency (Mild African form)	45mg per week for 8
G-6-PD deficiency (More severe Mediterranean variety)	30mg per week for 30 weeks

Should be avoided in pregnancy (the fetus is relatively G6PD-deficient & thus at risk of hemolysis) & G6PD deficiency patients







ADRS

<u>At regular doses</u> → patients with G-6-PD deficiency → hemolytic anemia.

At larger doses +

Epigastric distress & abdominal cramps

@Mild anemia, cyanosis & methemoglobinemia

Severe methemoglobinemia + rarely in patients with deficiency of NADPH methemoglobin reductase

@Granulocytopenia & agranulocytosis + rare.







ADRS



Oxidation of primaqune produces free radicals

@Free radicals will cause oxidative
damage of RBCs →Hemolysis

@H₂O₂ oxidizes GSH

Maintains integrity of RBCs



Til





IN FALICPARUM

SPECIAL RISK GROUPS

Pregnancy; 1st trimester

Pregnancy; 2nd & 3rd trimester Lactating women Infants & young children







Begin 1-2 weeks before departure (except for doxycycline 2 days) & continue for 4 weeks after leaving the endemic area.

THANK U....

37